Paradigm Biocapital Advisors LP - Sep 12, 2023 Form 3 Insider Report for Olema Pharmaceuticals, Inc. (OLMA)

Role: 10%+ Owner
Signature: /s/ David Kim, as an authorized signatory of the Fund and the Adviser GP (for itself and on behalf of the Adviser)
Stock symbol: OLMA
Transactions as of: Sep 12, 2023
Transactions value $: $0
Form type: 3
Date filed: 9/21/2023, 05:12 PM
Next filing: Dec 8, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	OLMA	Common Stock, par value $0.0001 per share						6.49M	Sep 12, 2023	By: Paradigm BioCapital International Fund Ltd.	F1
holding	OLMA	Common Stock, par value $0.0001 per share						1.31M	Sep 12, 2023	By: One or more separately managed accounts	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These securities are held directly by Paradigm BioCapital International Fund Ltd (the "Fund"). The Fund is a private investment vehicle. Paradigm BioCapital Advisors LP (the "Adviser") is the investment adviser of the Fund. Paradigm BioCapital Advisors GP LLC (the "Adviser GP") is the general partner of the Adviser. Senai Asefaw, M.D. is the managing member of the Adviser GP. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.
F2	These securities are held directly by one or more separately managed accounts managed by the Adviser. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.

Content

These securities are held directly by Paradigm BioCapital International Fund Ltd (the "Fund"). The Fund is a private investment vehicle. Paradigm BioCapital Advisors LP (the "Adviser") is the investment adviser of the Fund. Paradigm BioCapital Advisors GP LLC (the "Adviser GP") is the general partner of the Adviser. Senai Asefaw, M.D. is the managing member of the Adviser GP. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.

These securities are held directly by one or more separately managed accounts managed by the Adviser. Each Reporting Person disclaims beneficial ownership of all securities reported herein, except to the extent of their pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 of the Securities and Exchange Act of 1934 or for any other purpose.